Key Takeaways
- • Brevan Howard, a leading London-based macro hedge fund, has committed $200 million to Catalio Capital Management's healthcare-focused public equities fund through a separately managed account structure, enabling specialized sector exposure while retaining risk control.
- • Catalio Capital, co-founded by George Petrocheilos and Jacob Vogelstein, has delivered strong returns since its 2023 launch—49% net since inception and 12% net year-to-date through October 31, 2025—managing $2.3 billion across healthcare investments including pharmaceuticals, medical devices, and diagnostics.
- • The separately managed account arrangement allows Brevan Howard real-time visibility into all positions, risk monitoring, and faster exit mechanisms compared to traditional fund vehicles, addressing institutional investor concerns around transparency and liquidity.
- • The allocation reflects a broader industry shift toward specialist alpha strategies, with approximately 75% of multi-manager hedge funds now investing in niche-focused managers to access specialized expertise beyond generalist capabilities.
- • Catalio's leadership includes Ben Snedeker (former D.E. Shaw portfolio manager) and backing from institutional anchor investor KKR, providing credibility and operational expertise to support the fund's healthcare sector focus.
Summary
Brevan Howard Asset Management, one of the world's most prominent macro hedge funds based in London, has deployed $200 million into Catalio Capital Management's healthcare-focused public equities fund. The allocation represents a strategic bet on specialist expertise in a sector outside Brevan Howard's core macro competency, signaling confidence in Catalio's investment capabilities while acknowledging the value of delegated stock-picking authority in specialized domains.
The investment structure leverages a separately managed account (SMA), a mechanism increasingly favored by institutional capital allocators seeking granular control without sacrificing manager autonomy. Under this arrangement, Brevan Howard retains full visibility into Catalio's portfolio positions, maintains real-time risk exposure monitoring, and preserves the ability to terminate the relationship faster than would be possible with capital locked into a traditional fund vehicle. This hybrid control architecture appeals to institutional investors managing large capital bases and navigating regulatory or risk governance frameworks.
Catalio Capital, founded in 2023 by George Petrocheilos and Jacob Vogelstein, has established a track record attracting institutional capital. The fund generated 49% net returns since inception and posted 12% net performance through October 31, 2025. Catalio manages $2.3 billion across both public equity and private investment opportunities spanning pharmaceuticals, medical devices, diagnostics, and healthcare data companies. The firm's investment team includes Ben Snedeker, a portfolio manager with prior experience at D.E. Shaw, and has secured backing from KKR, a major global alternative investment firm, providing both credibility and operational infrastructure.
The Brevan Howard allocation exemplifies a broader market trend in which multi-manager hedge funds increasingly pursue specialist alpha through allocations to focused, niche-strategy managers. Industry research indicates approximately 75% of multi-strategy hedge funds now allocate capital to third-party managers with deep sector or strategy expertise, reflecting recognition that outperformance in specialized domains often requires dedicated domain knowledge and conviction-based positioning that generalist platforms struggle to achieve. For Brevan Howard, outsourcing healthcare equity selection to a dedicated specialist while retaining risk controls represents a pragmatic capital deployment strategy in an increasingly complex and bifurcated investment landscape.
The investment structure leverages a separately managed account (SMA), a mechanism increasingly favored by institutional capital allocators seeking granular control without sacrificing manager autonomy. Under this arrangement, Brevan Howard retains full visibility into Catalio's portfolio positions, maintains real-time risk exposure monitoring, and preserves the ability to terminate the relationship faster than would be possible with capital locked into a traditional fund vehicle. This hybrid control architecture appeals to institutional investors managing large capital bases and navigating regulatory or risk governance frameworks.
Catalio Capital, founded in 2023 by George Petrocheilos and Jacob Vogelstein, has established a track record attracting institutional capital. The fund generated 49% net returns since inception and posted 12% net performance through October 31, 2025. Catalio manages $2.3 billion across both public equity and private investment opportunities spanning pharmaceuticals, medical devices, diagnostics, and healthcare data companies. The firm's investment team includes Ben Snedeker, a portfolio manager with prior experience at D.E. Shaw, and has secured backing from KKR, a major global alternative investment firm, providing both credibility and operational infrastructure.
The Brevan Howard allocation exemplifies a broader market trend in which multi-manager hedge funds increasingly pursue specialist alpha through allocations to focused, niche-strategy managers. Industry research indicates approximately 75% of multi-strategy hedge funds now allocate capital to third-party managers with deep sector or strategy expertise, reflecting recognition that outperformance in specialized domains often requires dedicated domain knowledge and conviction-based positioning that generalist platforms struggle to achieve. For Brevan Howard, outsourcing healthcare equity selection to a dedicated specialist while retaining risk controls represents a pragmatic capital deployment strategy in an increasingly complex and bifurcated investment landscape.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.